Autosomal recessive nonsyndromic deafness 113 is a genetic condition that causes hearing loss without other medical features. It often presents from birth or early childhood and typically affects both ears. People with Autosomal recessive nonsyndromic deafness 113 notice trouble hearing speech, and families may observe poor response to sounds. Hearing loss is usually lifelong, but severity can vary. Treatment focuses on hearing support such as hearing aids, cochlear implants, and speech and language therapy, and most people have a normal life span.
Overview
Autosomal recessive nonsyndromic deafness 113Symptoms
Autosomal recessive nonsyndromic deafness 113 causes sensorineural hearing loss in both ears, usually from birth or early childhood, without other health issues. Signs include not reacting to sounds, speech delay, and needing higher volumes. Newborn hearing screening often detects it.
Outlook and prognosis
Many living with Autosomal recessive nonsyndromic deafness 113 do well with timely hearing support, such as hearing aids, cochlear implants, and communication tools. Hearing levels are typically stable and do not affect other body systems. With early identification, language, learning, and social development can thrive.
Causes and risk factors
Autosomal recessive nonsyndromic deafness 113 results from inheriting two faulty copies of a hearing gene from carrier parents. Risk increases with family history, parental relatedness, or certain ancestries. Loud noise or ototoxic drugs don’t cause it but can worsen hearing.
Genetic influences
Genetics are central to Autosomal recessive nonsyndromic deafness 113. Two nonworking gene copies are typically needed, often inherited from carrier parents. Specific gene variants influence age at onset, severity, and whether hearing loss is stable or progressive.
Diagnosis
Doctors suspect autosomal recessive nonsyndromic deafness 113 when hearing tests show congenital, nonprogressive inner-ear loss and no other features. The genetic diagnosis of autosomal recessive nonsyndromic deafness 113 is confirmed with genetic tests, supported by family history and, sometimes, imaging.
Treatment and drugs
Treatment for autosomal recessive nonsyndromic deafness 113 focuses on improving hearing and communication. Many benefit from hearing aids, bone‑conduction devices, or cochlear implants, plus speech-language therapy and classroom supports. Genetic counseling helps families understand inheritance and plan care.
Symptoms
Autosomal recessive nonsyndromic deafness 113 affects hearing without involving other parts of the body. Early features of Autosomal recessive nonsyndromic deafness 113 can appear at birth or in early childhood, ranging from mild to profound hearing loss. Features vary from person to person and can change over time. Families often first notice a missed newborn hearing screen or challenges responding to sound and developing clear speech.
This condition usually causes sensorineural hearing loss in both ears. Sounds may seem muffled or distant, especially soft speech. Louder speech can be clearer but still distorted.
Many children are born with hearing loss or develop it in the first few years. Caregivers may notice not startling to loud sounds or delayed responses to their name. For some with Autosomal recessive nonsyndromic deafness 113, hearing changes can emerge later in childhood.
Hearing loss can be mild, moderate, severe, or profound. It may stay stable or slowly worsen over time. Regular hearing tests help track any changes.
Because hearing is reduced, speech and language can develop more slowly. Kids may use fewer words, mispronounce sounds, or rely on gestures. Early support can help close the gap.
How people usually first notice Autosomal recessive nonsyndromic deafness 113?
Families often first notice autosomal recessive nonsyndromic deafness 113 in infancy when a baby doesn’t startle to loud sounds, doesn’t turn toward voices, or isn’t babbling as expected. Newborn hearing screening, which most hospitals perform within the first days of life, is a common way the first signs of autosomal recessive nonsyndromic deafness 113 are detected early, prompting repeat testing and referral to audiology. In some cases, milder hearing loss becomes clearer in early childhood when children miss soft speech sounds, turn up the volume, or have delayed speech, leading parents and teachers to recognize how autosomal recessive nonsyndromic deafness 113 is first noticed.
Types of Autosomal recessive nonsyndromic deafness 113
Autosomal recessive nonsyndromic deafness 113 is a genetic hearing-loss condition with recognized clinical variants based on which gene change is involved and whether hearing loss is present from birth or develops later. People with this condition typically have hearing differences without other health issues, but onset and severity can vary from mild to profound. Clinicians often describe them in these categories: congenital versus childhood-onset forms, and by the specific gene affected. When people search for types of Autosomal recessive nonsyndromic deafness 113, they’re usually asking about these well-established variants and how symptoms differ.
TMC1-related form
Hearing loss ranges from congenital and severe to later-onset and progressive. Many have stable, profound loss from birth, while others notice worsening across childhood or adolescence. Speech and balance are usually otherwise typical.
OTOF-related form
Often causes congenital, severe-to-profound hearing loss with normal outer hair cell tests but poor sound transmission to the hearing nerve. People may have absent auditory brainstem responses despite some cochlear activity. This pattern is consistent with auditory neuropathy.
MYO15A-related form
Typically presents at birth with profound, nonprogressive hearing loss. Many benefit from early cochlear implantation when hearing aids offer limited gain. Inner ear structure is usually normal on imaging.
GJB2-related form
Symptoms can range from mild to profound, and may be stable or slowly progressive. Some notice asymmetry between ears or fluctuating thresholds. Family histories often include relatives with early hearing loss.
LOXHD1-related form
Commonly presents in childhood with progressive loss that can advance from moderate to severe-profound. People may first struggle with soft speech or noisy settings, then need more powerful amplification over time. Balance is typically unaffected.
USH1C nonsyndromic alleles
Certain variants cause isolated hearing loss without the vision problems seen in Usher syndrome. Hearing loss is usually congenital and severe-profound. Care teams may still monitor vision periodically as a precaution.
ILDR1-related form
Often causes congenital, severe-to-profound loss that is generally nonprogressive. Extended families in certain regions may have multiple affected members due to shared ancestry. Early diagnosis supports timely language access.
TMPRSS3-related form
Can appear in childhood or adolescence and is frequently progressive. Some start with high-frequency loss that spreads to other pitches, affecting clarity first. Hearing aids may help early, with cochlear implants considered later.
TBC1D24 nonsyndromic alleles
Selected variants lead to isolated hearing loss without neurologic features seen in other TBC1D24 conditions. Onset may be congenital or early childhood. Progression varies by variant.
STRC-related form
Often causes mild-to-moderate, stable loss that can be hard to spot early. School hearing screens or difficulty hearing in noise may be the first clue. Many do well with hearing aids and classroom accommodations.
What genetics can tell you about symptoms
Some people with autosomal recessive nonsyndromic deafness 113 have changes in the TMPRSS3 gene that harm inner‑ear hair cells, causing early to progressive hearing loss. Different variants can shift timing and severity, from childhood onset to later, and from moderate to profound.
Causes and risk factors
Autosomal recessive nonsyndromic deafness 113 is caused by changes in a single gene that are inherited from both parents. Some risks are modifiable (things you can change), others are non-modifiable (things you can’t). Non-modifiable risks include having two carrier parents, a family history of similar hearing loss, or parents who are related by blood. Modifiable influences do not cause this condition, but loud noise and some antibiotics or chemotherapy medicines can worsen hearing or lead to earlier loss. Risk factors for autosomal recessive nonsyndromic deafness 113 can also cluster in communities with shared ancestry, so genetic counseling or testing can help clarify your personal risk.
Environmental and biological risk factors
Autosomal recessive nonsyndromic deafness 113 is often present from birth, so families naturally ask what might raise or lower the chance that it occurs. Current research suggests that environmental and biological risk factors for Autosomal recessive nonsyndromic deafness 113 are limited and not well defined. Awareness of both biological and environmental influences helps you feel prepared. Below are factors that studies have evaluated, and what is known so far.
No proven link to the occurrence of Autosomal recessive nonsyndromic deafness 113. Studies have not identified pregnancy or early-life exposures that trigger this specific condition. Research continues, but no specific exposure has been confirmed.
Common pregnancy illnesses, infections, or medicines have not been shown to cause Autosomal recessive nonsyndromic deafness 113. Good prenatal care is still important for overall fetal health.
Complications during delivery, prematurity, or newborn treatments are not known to create this form of hearing loss. This pattern helps distinguish it from other causes of congenital hearing loss.
Advanced maternal or paternal age has not been linked to higher risk for this condition. Available data do not show an age-related effect.
Genetic risk factors
The genetic cause involves changes in a single hearing‑related gene passed down in a recessive pattern. Some risk factors are inherited through our genes. The genetic causes of Autosomal recessive nonsyndromic deafness 113 center on inheriting one non‑working copy from each parent. Variants may be unique to a family or shared within certain ancestries.
Recessive inheritance: Autosomal recessive nonsyndromic deafness 113 happens when a child inherits two non‑working copies of the same hearing gene. Carriers with just one change usually have normal hearing. When both parents carry it, each pregnancy has a 25% chance of the condition.
Two gene changes: The condition requires changes in both copies of the gene associated with this condition. This can be the same change from each parent or two different changes that both disrupt the gene.
Carrier status: People can carry a single change linked to this condition without symptoms. Carrier frequency can cluster in families and communities, raising the chance two carriers have children together.
Family history pattern: In Autosomal recessive nonsyndromic deafness 113, you may see affected siblings with unaffected parents. Often there are no affected people in earlier generations, which can make the pattern easy to miss.
Parental relatedness: When parents are related by blood (consanguinity), they are more likely to share the same rare gene change. This raises the chance a child will inherit two copies and develop the condition.
Founder variants: In some ancestries or small communities, a single older gene change can be more common. If both parents come from that group, the risk of Autosomal recessive nonsyndromic deafness 113 may be higher.
Lifestyle risk factors
Autosomal recessive nonsyndromic deafness 113 is inherited; lifestyle habits do not cause it. However, daily choices can influence residual hearing, communication access, and risk of complications such as ear infections. Understanding how lifestyle affects Autosomal recessive nonsyndromic deafness 113 can help protect any remaining hearing and optimize hearing technology benefits. Below are practical lifestyle risk factors for Autosomal recessive nonsyndromic deafness 113 to consider in day-to-day life.
Regular exposure to loud concerts, clubs, or high-volume headphones can further reduce residual hearing and worsen tinnitus. Keep volumes moderate and use hearing protection in loud settings.
Shooting sports, power tools, and motorsports without protection can accelerate hearing decline. Wear well-fitted earplugs or earmuffs and limit duration of exposure.
Some antibiotics, chemotherapy agents, and high-dose loop diuretics can damage inner-ear cells. Review medication lists with clinicians and ask about hearing-safe alternatives and monitoring.
Tobacco smoke and nicotine can impair inner-ear blood flow and increase middle-ear infections. Avoid smoking and minimize secondhand smoke to protect remaining hearing and reduce infection risk.
Risk prevention
Autosomal recessive nonsyndromic deafness 113 is an inherited form of hearing loss, so there’s no way to stop it from developing after conception. Prevention is about lowering risk, not eliminating it completely. Family planning tools can reduce the chance of having an affected child, and early detection helps protect speech and learning. Ongoing hearing care also reduces complications over time.
Before pregnancy, a simple blood or saliva test can show if you carry the gene change linked to this condition. If both partners are carriers, each pregnancy has about a 1 in 4 chance of autosomal recessive nonsyndromic deafness 113.
If you know you carry a relevant gene change, ask to test your partner. Knowing both results clarifies the chance of having a child with this inherited hearing loss.
A genetics professional can explain inheritance, your family’s chances, and choices for future pregnancies. They can also help you plan testing for relatives and discuss support if a child is affected.
In vitro fertilization with embryo testing (PGT-M), donor sperm or eggs, or prenatal testing can lower the chance of having a child with autosomal recessive nonsyndromic deafness 113. Talk to your doctor about which preventive steps are right for you.
Transmission
Autosomal recessive nonsyndromic deafness 113 is inherited, not caught from others, so it isn’t contagious. It follows an autosomal recessive pattern, meaning a child needs to inherit two nonworking copies of the same gene—one from each parent—to have the condition. Parents who each carry one nonworking copy typically have usual hearing, but with each pregnancy there is a 25% (1 in 4) chance their child will have Autosomal recessive nonsyndromic deafness 113, a 50% (1 in 2) chance the child will be a carrier like them, and a 25% (1 in 4) chance the child will inherit neither change. New gene changes can occur, but genetic transmission of Autosomal recessive nonsyndromic deafness 113 most often happens when both parents are carriers, and it affects people of any sex equally.
When to test your genes
Consider genetic testing if you have early-onset hearing loss without other health issues, a family history of similar deafness, or relatives known to carry GJB2/GJB6 variants. Testing helps confirm Autosomal recessive nonsyndromic deafness 113 and guides hearing care, counseling, and family planning. Newborns or siblings with unexplained hearing loss also benefit.
Diagnosis
For many families, the first signs are practical: a baby who doesn’t startle at loud noises, a toddler who doesn’t turn to a voice, or a child who needs the TV louder than others. For some, routine check-ups reveal the first clues. Doctors usually begin by confirming the type and degree of hearing loss and checking for features that might suggest a broader syndrome. From there, testing can confirm whether the hearing loss is genetic, including the diagnosis of Autosomal recessive nonsyndromic deafness 113.
Hospitals screen hearing within days of birth using quick, painless sounds-and-response checks. A referral or “not pass” result means more testing is needed to confirm hearing loss.
Audiologists measure how well the ear and hearing nerve respond, often with ABR, OAE, and age-appropriate audiograms. Tests may feel repetitive, but each one helps rule out different causes.
An ear, nose, and throat specialist examines the ears, eardrum, and head-and-neck features. Doctors may perform a general physical exam to look for clues of a broader syndrome.
Clinicians ask about relatives with hearing loss, age at onset, and any patterns across generations. Family history is often a key part of the diagnostic conversation.
Stages of Autosomal recessive nonsyndromic deafness 113
Autosomal recessive nonsyndromic deafness 113 does not have defined progression stages. Because early symptoms of Autosomal recessive nonsyndromic deafness 113 are mostly limited to hearing changes that can be present from birth or develop in childhood, it’s monitored with hearing tests rather than a step-by-step staging system. Different tests may be suggested to help map your hearing profile and rule out other causes, including newborn screening, audiology (tone and speech testing), otoacoustic emissions, and sometimes auditory brainstem response. Genetic testing is often used to confirm the diagnosis and to guide family planning.
Outlook and prognosis
Living with Autosomal recessive nonsyndromic deafness 113 (DFNB113) often means navigating permanent hearing loss from birth or early childhood, typically without other health problems. Many people ask, “What does this mean for my future?”, and the short answer is that life expectancy is normal and day‑to‑day health is otherwise unaffected for most. The biggest impacts show up in communication—hearing speech in classrooms, following conversations in group settings, or catching soft sounds like doorbells. Early care can make a real difference, including newborn screening, timely hearing aids or cochlear implants when appropriate, and family-centered speech or sign language support.
The outlook is not the same for everyone, but hearing levels in DFNB113 tend to be stable rather than steadily worsening. Doctors call this the prognosis—a medical word for likely outcomes. There’s no evidence that DFNB113 on its own raises the risk of other medical problems or shortens life, and mortality is not increased compared with the general population. That said, the early symptoms of Autosomal recessive nonsyndromic deafness 113 can shape school readiness, language development, and social confidence, which is why prompt assessment and consistent follow‑up matter.
With ongoing care, many people maintain strong communication skills, independence, and employment across the lifespan. Looking at the long-term picture can be helpful. Supports such as classroom accommodations, captioning, and hearing technology can reduce listening effort and fatigue, and learning sign language can offer a clear, reliable channel for communication. Talk with your doctor about what your personal outlook might look like, including whether genetic testing could clarify the specific gene involved and what to expect over time.
Long-term effects
In Autosomal recessive nonsyndromic deafness 113, hearing challenges usually start early and persist across life stages. Long-term effects vary widely, and can look different from one family to the next. For many, hearing levels are stable; for others, they may slowly change over time. These lifelong hearing differences can influence speech, learning, social connection, and day-to-day safety awareness.
Hearing loss is typically sensorineural and can range from moderate to profound. It may remain steady or gradually shift over years. Doctors may track these changes over years to see how stable the hearing levels are.
Early signs of Autosomal recessive nonsyndromic deafness 113 may include delayed babbling or fewer responses to sounds. Without clear sound access, spoken language can develop later or differently. Many develop strong language through visual or auditory pathways depending on hearing level.
Some people develop speech that sounds less clear, especially if hearing loss began before speech formed. Speech patterns often reflect how much sound input was available in early years. Clarity can vary widely across individuals.
Thinking and learning ability are not affected by the hearing condition itself. Access to sound or visual information in class can shape reading, participation, and test performance over time. With consistent access, academic progress is often similar to hearing peers.
How is it to live with Autosomal recessive nonsyndromic deafness 113?
Life with autosomal recessive nonsyndromic deafness 113 often centers on communication choices and access—many people rely on sign language, lip-reading, hearing aids, or cochlear implants, and success varies with early support and consistent practice. Day to day, this can mean planning for quiet spaces, clear lighting for lip-reading, captioned media, and alert systems that use light or vibration instead of sound. School and work are very doable with accommodations—interpreters, captioning, and accessible meetings—while friends and family learn small habits like facing you when speaking, avoiding talking from another room, and reducing background noise. With inclusive environments and timely audiology and educational support, most build strong connections and independent routines, and those around them often describe deeper, more intentional communication.
Treatment and drugs
Autosomal recessive nonsyndromic deafness 113 is managed by improving access to sound, supporting communication, and addressing day-to-day needs rather than changing the underlying gene. For many people, treatment begins with small daily steps like well-fitted hearing aids, classroom or workplace assistive devices, and speech and language therapy to build clear communication skills. If hearing loss is severe to profound, cochlear implants may help by sending sound signals directly to the hearing nerve; doctors will assess hearing tests, inner ear structure, and real‑world listening goals to decide if this is a good option. Alongside medical treatment, lifestyle choices play a role, including protecting any remaining hearing, managing background noise, using captioning, and learning sign language if that suits your communication style. Regular follow-up with audiology and ear, nose, and throat specialists helps fine‑tune devices and settings over time, and genetic counseling can guide family planning and connect you with resources.
Non-drug treatment
For many families, the focus is on building strong communication from the start. Non-drug treatments often lay the foundation for daily life, schooling, and social connection. Early symptoms of Autosomal recessive nonsyndromic deafness 113 can be subtle in babies, so early hearing checks and prompt support matter. People with Autosomal recessive nonsyndromic deafness 113 can thrive with tailored devices, education, and therapy.
Hospital or community hearing tests can flag possible hearing loss in the first days of life. Quick follow-up with a pediatric audiologist helps confirm results and start support early.
Speech, language, and family support services can begin in infancy. Starting before 6 months often improves later communication and learning.
Modern digital aids amplify the sounds someone can still hear. For Autosomal recessive nonsyndromic deafness 113, careful fitting and routine adjustments help match changing needs.
For severe to profound hearing loss, an implant can directly stimulate the hearing nerve. Many children with Autosomal recessive nonsyndromic deafness 113 gain clearer access to speech with early implantation.
Your genes may have an impact on how drugs work for you
Some medicines used around hearing care—like certain antibiotics or chemotherapy drugs—can be riskier for people with specific genetic changes that make inner‑ear cells more vulnerable. Pharmacogenetic testing can sometimes guide safer choices or dosing, though it doesn’t replace routine hearing monitoring.
Pharmacological treatments
For autosomal recessive nonsyndromic deafness 113, there are currently no approved medicines that restore hearing; care centers on hearing aids or cochlear implants. Alongside drug therapy, hearing devices and communication strategies remain important. Medicines may still be used for related issues like ear infections, surgery prevention, or rare episodes of sudden hearing loss. These drugs will not change early symptoms of autosomal recessive nonsyndromic deafness 113, but they can protect ear health and support implant safety.
Short courses may be used if a sudden sensorineural hearing loss is suspected to be inflammatory. This is not helpful for stable, lifelong genetic hearing loss such as autosomal recessive nonsyndromic deafness 113. Dosing may be increased or lowered gradually to reduce side effects.
Treats middle-ear infections that temporarily worsen hearing, especially in children. Amoxicillin or amoxicillin–clavulanate is commonly used; azithromycin is an option if you are allergic to penicillin. These do not treat the underlying genetic deafness.
Used for outer or draining ear infections when they occur. They reduce swelling and control bacteria in the ear canal. They do not improve baseline hearing from genetic causes.
Given around cochlear implant surgery to lower infection risk. A single pre‑operative dose of cefazolin is typical; clindamycin may be used if you have a severe penicillin allergy. This protects the implant and surrounding tissue but does not change hearing levels.
Genetic influences
In most families, this form of hearing loss appears when a child inherits two nonworking copies of the same gene—one from each parent. Autosomal recessive nonsyndromic deafness 113 is inherited in a recessive way: if both parents carry the gene change, each pregnancy has a 25% (1 in 4) chance of a child with the condition, a 50% (1 in 2) chance of a child who is a carrier, and a 25% chance of a child with no copy of the change. A “carrier” means you hold the gene change but may not show symptoms. Because this is a nonsyndromic type, people with autosomal recessive nonsyndromic deafness 113 typically have hearing loss without other medical features. Severity and the exact hearing pattern can differ between families and even between siblings, depending on the specific gene change. Genetic testing for autosomal recessive nonsyndromic deafness 113 can sometimes confirm the diagnosis, identify carriers in the family, and inform reproductive options. A consultation with a genetic counselor can help you understand your family’s chances and how results may guide next steps.
Is Autosomal recessive nonsyndromic deafness 113 genetic?
Genetics are central to Autosomal recessive nonsyndromic deafness 113. Two nonworking gene copies are typically needed, often inherited from carrier parents. Specific gene variants influence age at onset, severity, and whether hearing loss is stable or progressive.
Pharmacogenetics—how genetics influence drug effects
Care for this condition often involves devices and procedures rather than daily medicines, but genetics still matter when drugs are used before surgery, to treat infections, or for other health needs. In Autosomal recessive nonsyndromic deafness 113, the main pharmacogenetic concern is protecting any remaining hearing: separate from the gene change causing the deafness, some people carry mitochondrial variants that make aminoglycoside antibiotics highly ototoxic, so your team may avoid these drugs or use alternatives. Genetic testing can sometimes identify how your body handles certain medicines, guiding choices for antibiotics and pain relievers after procedures. For example, some people break down codeine too slowly or too quickly, which can lead to poor pain control or more side effects; your doctor can choose a different pain medicine if needed. If chemotherapy such as cisplatin is ever required for an unrelated condition, genes may also influence the chance of drug-related hearing damage, so extra monitoring and hearing protection strategies may be planned. Put simply, pharmacogenetic testing for Autosomal recessive nonsyndromic deafness 113 isn’t about treating the hearing loss itself, but about tailoring the surrounding medications to be safer and more effective.
Interactions with other conditions
Autosomal recessive nonsyndromic deafness 113 mainly affects hearing, so other body systems aren’t expected to be involved. Still, common ear problems can interact with it: recurrent ear infections, wax buildup, or seasonal allergies can temporarily lower hearing further, making early symptoms of Autosomal recessive nonsyndromic deafness 113 harder to notice. Doctors call it a “comorbidity” when two conditions occur together. Certain medicines that are hard on the inner ear—like some antibiotics (aminoglycosides), chemotherapy drugs (such as cisplatin), and high-dose loop diuretics—may worsen existing hearing loss, so it’s important that any prescriber knows about the diagnosis.
Noise exposure at work or loud concerts can add to inner-ear damage over time, and age-related hearing changes can layer on top of genetic loss. Mental health conditions, including anxiety or depression, can also intersect, especially if communication becomes more challenging in school, at work, or socially. Balance problems usually aren’t a feature, so new dizziness or vision changes should prompt a check for other causes. Talk with your doctor about how your conditions may influence each other, and ask if any medications for one condition might interfere with treatment for another.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described children born with typical growth and learning who did not respond to sound, even when speech and the ears looked normal. Families told stories of siblings who signed to each other at home, or a cousin who seemed to hear vibrations but not voices. These everyday observations captured what we now recognize as autosomal recessive nonsyndromic deafness 113: hearing loss present from birth or early childhood without other health differences.
First described in the medical literature as clusters of hearing loss within extended families, early reports focused on patterns—two unaffected parents having more than one child with significant hearing loss. Before modern testing, doctors relied on bedside exams and tuning forks. Over time, descriptions became more precise as audiograms showed stable, usually severe to profound hearing loss affecting both ears, while balance, vision, and development were otherwise typical. This set it apart from “syndromic” forms, where hearing loss comes with other features.
In recent decades, knowledge has built on a long tradition of observation. As medical science evolved, family studies and then genetic tools confirmed what communities had noticed: an autosomal recessive inheritance pattern, meaning a child is affected when they inherit two nonworking copies of a specific gene, one from each parent. The “113” simply marks this condition’s place among many named genetic types of nonsyndromic hearing loss, rather than ranking severity or importance.
Advances in genetics turned patterns on family trees into precise diagnoses. Researchers matched consistent hearing test results with changes in a single gene, showing that the inner ear’s sensory cells were affected while the rest of the body was not. This explained why early symptoms of autosomal recessive nonsyndromic deafness 113 centered on hearing alone, and why parents—who carry one nonworking copy—typically hear normally.
Despite evolving definitions, the central picture has stayed steady: early-onset, bilateral hearing loss without other associated medical findings, seen in more than one child in a family, especially when parents are related or come from smaller communities. Newborn hearing screening broadened awareness by identifying babies within days of birth, allowing earlier language access through sign language, hearing technology, or both.
Today, the history of autosomal recessive nonsyndromic deafness 113 connects careful family stories, classic clinical exams, and modern gene testing. Knowing the condition’s history helps explain why some families have long recognized a recurring pattern, and how current tools can offer clear answers while respecting the wide range of communication choices and thriving lives within the Deaf and hard of hearing communities.